Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.

Frontiers in pharmacology

Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO.
PMID: 33833683
Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021.

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or...

Cite
Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol. 2021;12:633680doi: 10.3389/fphar.2021.633680.
Malone, R. W., Tisdall, P., Fremont-Smith, P., Liu, Y., Huang, X. P., White, K. M., Miorin, L., Moreno, E., Alon, A., Delaforge, E., Hennecker, C. D., Wang, G., Pottel, J., Blair, R. V., Roy, C. J., Smith, N., Hall, J. M., Tomera, K. M., Shapiro, G., Mittermaier, A., Kruse, A. C., García-Sastre, A., Roth, B. L., Glasspool-Malone, J., & Ricke, D. O. (2021). COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Frontiers in pharmacology, 12633680. https://doi.org/10.3389/fphar.2021.633680
Malone, Robert W, et al. "COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms." Frontiers in pharmacology vol. 12 (2021): 633680. doi: https://doi.org/10.3389/fphar.2021.633680
Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021. PMID: 33833683; PMCID: PMC8021898.
Copy Download .nbib Format: NLM
Use of adjunctive prednisolone in the management of a cat with bilateral quadriceps contracture following trauma.

JFMS open reports

Tisdall PL, Rogowski CP.
PMID: 28491455
JFMS Open Rep. 2017 Mar 14;3(1):2055116917695876. doi: 10.1177/2055116917695876. eCollection 2017.

CASE SUMMARY: A 6-month-old cat was successfully treated for bilateral quadriceps contracture. Conventional treatments including surgery, dynamic flexion apparatus and physical therapy along with analgesics and non-steroidal anti-inflammatory drugs resulted in temporary clinical improvement that was relapsing. The initiation...

Cite
Tisdall PL, Rogowski CP. Use of adjunctive prednisolone in the management of a cat with bilateral quadriceps contracture following trauma. JFMS Open Rep. 2017;3(1):2055116917695876doi: 10.1177/2055116917695876.
Tisdall, P. L., & Rogowski, C. P. (2017). Use of adjunctive prednisolone in the management of a cat with bilateral quadriceps contracture following trauma. JFMS open reports, 3(1), 2055116917695876. https://doi.org/10.1177/2055116917695876
Tisdall, Penelope Lc, and Rogowski, Cameron P. "Use of adjunctive prednisolone in the management of a cat with bilateral quadriceps contracture following trauma." JFMS open reports vol. 3,1 (2017): 2055116917695876. doi: https://doi.org/10.1177/2055116917695876
Tisdall PL, Rogowski CP. Use of adjunctive prednisolone in the management of a cat with bilateral quadriceps contracture following trauma. JFMS Open Rep. 2017 Mar 14;3(1):2055116917695876. doi: 10.1177/2055116917695876. eCollection 2017. PMID: 28491455; PMCID: PMC5415297.
Copy Download .nbib Format: NLM
Models for COVID-19 Early Cardiac Pathology Following SARS-CoV-2 Infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Fremont-Smith M, Gherlone N, Smith N, Tisdall P, Ricke DO.
PMID: 34592443
Int J Infect Dis. 2021 Dec;113:331-335. doi: 10.1016/j.ijid.2021.09.052. Epub 2021 Sep 27.

OBJECTIVES: The clinical manifestations of COVID-19 associated cardiac complications are heterogeneous, ranging from asymptomatic to severe symptoms, including arrhythmias and cardiogenic shock. For COVID-19 patients with cardiac sequela, only a small subset of patients have myocarditis; the pathogenesis of...

Cite
Fremont-Smith M, Gherlone N, Smith N, et al. Models for COVID-19 Early Cardiac Pathology Following SARS-CoV-2 Infection. Int J Infect Dis. 2021;113:331-335doi: 10.1016/j.ijid.2021.09.052.
Fremont-Smith, M., Gherlone, N., Smith, N., Tisdall, P., & Ricke, D. O. (2021). Models for COVID-19 Early Cardiac Pathology Following SARS-CoV-2 Infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 113331-335. https://doi.org/10.1016/j.ijid.2021.09.052
Fremont-Smith, Maurice, et al. "Models for COVID-19 Early Cardiac Pathology Following SARS-CoV-2 Infection." International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases vol. 113 (2021): 331-335. doi: https://doi.org/10.1016/j.ijid.2021.09.052
Fremont-Smith M, Gherlone N, Smith N, Tisdall P, Ricke DO. Models for COVID-19 Early Cardiac Pathology Following SARS-CoV-2 Infection. Int J Infect Dis. 2021 Dec;113:331-335. doi: 10.1016/j.ijid.2021.09.052. Epub 2021 Sep 27. PMID: 34592443; PMCID: PMC8473263.
Copy Download .nbib Format: NLM
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.

Research square

Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Olmo EMD, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Smith N, Hall JM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO.
PMID: 32702719
Res Sq. 2020 Jun 22; doi: 10.21203/rs.3.rs-30934/v2.

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease,...

Cite
Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Res Sq. 2020;doi: 10.21203/rs.3.rs-30934/v2.
Malone, R. W., Tisdall, P., Fremont-Smith, P., Liu, Y., Huang, X. P., White, K. M., Miorin, L., Olmo, E. M. D., Alon, A., Delaforge, E., Hennecker, C. D., Wang, G., Pottel, J., Smith, N., Hall, J. M., Shapiro, G., Mittermaier, A., Kruse, A. C., García-Sastre, A., Roth, B. L., Glasspool-Malone, J., & Ricke, D. O. (2020). COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Research square, . https://doi.org/10.21203/rs.3.rs-30934/v2
Malone, Robert W, et al. "COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms." Research square vol. (2020). doi: https://doi.org/10.21203/rs.3.rs-30934/v2
Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Olmo EMD, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Smith N, Hall JM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Res Sq. 2020 Jun 22; doi: 10.21203/rs.3.rs-30934/v2. PMID: 32702719; PMCID: PMC7336703.
Copy Download .nbib Format: NLM
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.

Frontiers in pharmacology

Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO.
PMID: 33833683
Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021.

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or...

Cite
Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol. 2021;12:633680doi: 10.3389/fphar.2021.633680.
Malone, R. W., Tisdall, P., Fremont-Smith, P., Liu, Y., Huang, X. P., White, K. M., Miorin, L., Moreno, E., Alon, A., Delaforge, E., Hennecker, C. D., Wang, G., Pottel, J., Blair, R. V., Roy, C. J., Smith, N., Hall, J. M., Tomera, K. M., Shapiro, G., Mittermaier, A., Kruse, A. C., García-Sastre, A., Roth, B. L., Glasspool-Malone, J., & Ricke, D. O. (2021). COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Frontiers in pharmacology, 12633680. https://doi.org/10.3389/fphar.2021.633680
Malone, Robert W, et al. "COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms." Frontiers in pharmacology vol. 12 (2021): 633680. doi: https://doi.org/10.3389/fphar.2021.633680
Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021. PMID: 33833683; PMCID: PMC8021898.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries